Plasma Lysyl-tRNA Synthetase 1 (KARS1) as a Novel Diagnostic and Monitoring Biomarker for Colorectal Cancer
Authors:
- Ji Hun SuhJSJi Hun Suh
- Min Chul ParkMPMin Chul Park
- Peter C. GoughnourPGPeter C. Goughnour
- Byung Soh MinBMByung Soh Min
- Sang Bum KimSKSang Bum Kim
- Woo Yong LeeWLWoo Yong Lee
- Yong Beom ChoYCYong Beom Cho
- Jae Hee CheonJCJae Hee Cheon
- Kang Young LeeKLKang Young Lee
- Do-Hyun NamDNDo-Hyun Nam
- Sunghoon KimSKSunghoon Kim
Open Access
- 15 February 2020
- journal article
- research article
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 9 (2) , 533
Abstract
Colorectal cancer (CRC) is one of the leading causes of world cancer deaths. To improve the survival rate of CRC, diagnosis and post-operative monitoring is necessary. Currently, biomarkers are used for CRC diagnosis and prognosis. However, these biomarkers have limitations of specificity and sensitivity. Levels of plasma lysyl-tRNA synthetase (KARS1), which was reported to be secreted from colon cancer cells by stimuli, along with other secreted aminoacyl-tRNA synthetases (ARSs), were analyzed in CRC and compared with the currently used biomarkers. The KARS1 levels of CRC patients (n = 164) plasma were shown to be higher than those of healthy volunteers (n = 32). The diagnostic values of plasma KARS1 were also evaluated by receiving operating characteristic (ROC) curve. Compared with other biomarkers and ARSs, KARS1 showed the best diagnostic value for CRC. The cancer specificity and burden correlation of plasma KARS1 level were validated using azoxymethane (AOM)/dextran sodium sulfate (DSS) model, and paired pre- and post-surgery CRC patient plasma. In the AOM/DSS model, the plasma level of KARS1 showed high correlation with number of polyps, but not for inflammation. Using paired pre- and post-surgery CRC plasma samples (n = 60), the plasma level of KARS1 was significantly decreased in post-surgery samples. Based on these evidence, KARS1, a surrogate biomarker reflecting CRC burden, can be used as a novel diagnostic and post-operative monitoring biomarker for CRC.Keywords
Funding Information
- National Research Foundation funded by the Ministry of Science and ICT (MSIT) of Korea (NRF-M3A6A4-2010-0029785)
This publication has 46 references indexed in Scilit:
- The Pitfalls of CA19-9American Journal of Clinical Pathology, 2012
- Identification of a biomarker panel for colorectal cancer diagnosisBMC Cancer, 2012
- Septin 9 methylated DNA is a sensitive and specific blood test for colorectal cancerBMC Medicine, 2011
- Aminoacyl-tRNA synthetases and tumorigenesis: more than housekeepingNature Reviews Cancer, 2011
- Patient-Reported Barriers to Colorectal Cancer ScreeningAmerican Journal of Preventive Medicine, 2010
- Multiple serological biomarkers for colorectal cancer detectionInternational Journal of Cancer, 2010
- The role of chemokines in intestinal inflammation and cancerCurrent Opinion in Pharmacology, 2009
- Aminoacyl tRNA synthetases and their connections to diseaseProceedings of the National Academy of Sciences, 2008
- An inducible mouse model of colon carcinogenesis for the analysis of sporadic and inflammation-driven tumor progressionNature Protocols, 2007
- Follow-Up Recommendations for Colon CancerClinics in Colon and Rectal Surgery, 2005